Praxis Precision Medicines, Inc.
elsunersen
early-seizure-onset SCN2A DEE
Countdown
542days
Phase 3 readout · ~ Dec 31, 2027 estimated
What's at stake
Phase 3 trial results for elsunersen in early-seizure-onset SCN2A DEE are due ~ Dec 31, 2027. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 14h ago
“In December 2025, Praxis shared that after a favorable meeting with the FDA there was agreement to update the EMBRAVE3 registrational trial design by removing the sham control arm. Enrollment is underway, with topline results expected in 20”